Skip to main content
. 2020 Apr 21;225(8):1399–1410. doi: 10.1093/infdis/jiaa121

Figure 5.

Figure 5.

Cytokine-positive CD4 and CD8 T-cell response induced by HB-101 vaccination in healthy subjects. Percentage of cytomegalovirus glycoprotein B (gB)-specific (A), pp65-specific (B), and lymphocytic choriomeningitis virus (LCMV) nucleoprotein (NP)-specific CD4 and CD8 T cells (C) secreting at least 1 of the cytokines, interferon-γ, interleukin-2, or tumor necrosis factor during the study period are illustrated. Arrows indicate time of vaccine administration. Data shown are means ± standard error of the mean (SEM). Significant differences (*, P < .05; **, P < .0001; Kruskal-Wallis’s test) between the placebo and vaccine groups at Month 4 for cytomegalovirus pp65 + CD8 T, cytomegalovirus gB + CD4 T, LCMV NP + CD4 and CD8 T cells, but not for cytomegalovirus pp65 + CD4 (P = .579) or gB + CD8 T cells (P = .065). (D) Percentages of CD8 and CD4 T-cell responders at Week 14. Responders to cytomegalovirus gB only, pp65 only, both gB and pp65, and NP are color coded. A responder was defined as a subject whose frequency of cytokine-secreting CD4 or CD8 T cells increased to >2-fold the individual’s baseline on Day 0.